Target ALS is a privately funded consortium of researchers from academic and biotech/pharma laboratories entirely focused on finding a treatment for patients living with ALS. We fund research consortia, Springboard Fellowships for emerging research leaders, and nationwide core facilities. Here are some questions we are often asked:
What is the immediate goal of Target ALS?
To increase the number and quality of ALS drug development programs pursued by the biotech/pharma industry. We do this by supporting and coordinating the best academic research, by providing core facilities that remove critical bottlenecks and by catalyzing and funding direct collaborations between academia and biotech/pharma.
Who provides funding for Target ALS research?
Our founding donors, Dan Doctoroff, David Rubenstein and Bloomberg Philanthropies provided 3-year funding of $25M, which has been supplemented by more than $1M from other anonymous donors. Increasingly, members of the public have expressed their wish to support this unique effort.
Who receives Target ALS funding?
A total of 52 academic laboratories, an increasing number of industry partners, as well as independent cutting-edge contract research organizations who execute the work of the core facilities.
Who administers Target ALS funding?
Target ALS funds are administered following due process by Target ALS Foundation, a non-profit 501©(3) organization.
Site |
Badges |
|
Target ALS
, ,
United States
|
|
|
Target ALS
, ,
United States
|
|